the satiety question that gets asked weekly, answered properly
the satiety question that gets asked weekly, answered properly, and I am aware this is a minority view on this board.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
read the combination arms separately from the monotherapy arms
read the combination arms separately from the monotherapy arms
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
do not assume the dosing intuitions from the GLP-1 boards transfer
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
long-acting amylin is the whole point of the molecule
Retitled to distinguish the combination arm from the monotherapy arm, which the original ran together.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
nothing here is approved as a standalone product and research material is not for human use
nothing here is approved as a standalone product and research material is not for human use
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
nothing containing this is approved as a standalone product
Do you have the publication or a summary of it?
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
phase 3 data will change most of what gets said here
- 1Retitled to distinguish the combination arm from the monotherapy arm, which…11 comments in this branch · started by u/ledger_mod